Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-Cell tolerance

Cancer Research

Volumn 73, Issue 2, 2013, Pages 605-616

  Berrien Elliott, Melissa M ^a   Jackson, Stephanie R ^a   Meyer, Jennifer M ^a   Rouskey, Craig J ^a   Nguyen, Thanh Long M ^a   Yagita, Hideo ^c   Greenberg, Philip D ^d,e   DiPaolo, Richard J ^a,b   Teague, Ryan M ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b S Louis Univ Hlth Sciences Center   (United States)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LAG3 PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELL TRANSFER; CONTROLLED STUDY; CYTOLYSIS; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN VIVO STUDY; LEUKEMIA; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CTLA-4 ANTIGEN; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, TRANSGENIC; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR ESCAPE;

EID: 84872535167     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2179     Document Type: Article

References (50)

1. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305: 200-5.
2. Finn OJ. Cancer immunology. N Engl J Med 2008;358: 2704-15.
3. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314: 126-9.
4. Morimoto J, Tan X, Teague RM, Ohlen C, Greenberg PD. Induction of tolerance in CD8+ T cells to a transgenic autoantigen expressed in the liver does not require cross-presentation. J Immunol 2007;178: 6849-60.
5. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8: 299-308.
6. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigen-specific CD8+ T-cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T-cells. Proc Natl Acad Sci U S A 2002;99: 16168-73.
7. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995;3: 87-98.
8. Fife BT, Bluestone JA. Control of peripheral T cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166-82.
9. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T-cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005;6: 280-6.
10. Martin-Orozco N, Wang YH, Yagita H, Dong C. Cutting edge: programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ Tcell tolerance to tissue antigens. J Immunol 2006;177: 8291-5.
11. Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, Lowe D, et al. Program death-1 engagement uponTCRactivation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol 2003;170: 711-8.
12. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002;25: 243-51.
13. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T-cells. J Clin Invest 2005;115: 1616-26.
14. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7: 445-50.
15. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. Molecular basis of T-cell inactivation by CTLA-4. Science 1998;282: 2263-6.
16. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2009;15: 6446-53.
17. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010;16: 2861-71.
18. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271: 1734-6.
19. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100: 8372-7.
20. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX- 1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28: 3167-75.
21. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T-cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107: 4275-80.
22. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65: 1089-96.
23. Matsuzaki J, Gnjatic S,Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T-cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010;107: 7875-80.
24. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010;9: 767-74.
25. Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T-cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A 2009;106: 17469-74.
26. Kuball J, Hauptrock B, Malina V, Antunes E, Voss RH, Wolfl M, et al. Increasing functional avidity of TCR-redirected T-cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med 2009;206: 463-75.
27. Teague RM, Greenberg PD, Fowler C, Huang MZ, Tan X, Morimoto J, et al. Peripheral CD8+ T-cell tolerance to self-proteins is regulated proximally at the T-cell receptor. Immunity 2008;28: 662-74.
28. Turtle CJ, Riddell SR. Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr Opin Immunol 2011;23: 299-305.
29. Ohlen C, Kalos M, Hong DJ, Shur AC, Greenberg PD. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T-cells or CTL immunotherapy of tumors expressing the antigen. J Immunol 2001;166: 2863-70.
30. Ohlen C, Kalos M, Cheng LE, Shur AC, Hong DJ, Carson BD, et al. CD8 (+) T-cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med 2002; 195: 1407-18.
31. Chen W, Qin H, Chesebro B, Cheever MA. Identification of a gagencoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol 1996;70: 7773-82.
32. Teague RM, Sather BD, Sacks JA, Huang MZ, Dossett ML, Morimoto J, et al. Interleukin-15 rescues tolerant CD8+ T-cells for use in adoptive immunotherapy of established tumors. Nat Med 2006;12: 335-41.
33. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med 2005;11: 1299-305.
34. Macintyre AN, Finlay D, Preston G, Sinclair LV, Waugh CM, Tamas P, et al. Protein kinase B controls transcriptional programs that direct cytotoxic T-cell fate but is dispensable for T-cell metabolism. Immunity 2011;34: 224-36.
35. Davey GM, Kurts C, Miller JF, Bouillet P, Strasser A, Brooks AG, et al. Peripheral deletion of autoreactive CD8 T-cells by cross presentation of self-antigen occurs by a Bcl-2-inhibitable pathway mediated by Bim. J Exp Med 2002;196: 947-55.
36. Holz LE, Bowen DG, Bertolino P. Mechanisms of T-cell death in the liver: to Bim or not to Bim? Dig Dis 2010;28: 14-24.
37. Redmond WL, Wei CH, Kreuwel HT, Sherman LA. The apoptotic pathway contributing to the deletion of naive CD8 T-cells during the induction of peripheral tolerance to a cross-presented self-antigen. J Immunol 2008;180: 5275-82.
38. Bouillet P, O'Reilly LA. CD95, BIM and T-cell homeostasis. Nat Rev Immunol 2009;9: 514-9.
39. Parish IA, Rao S, Smyth GK, Juelich T, Denyer GS, Davey GM, et al. The molecular signature of CD8+ T-cells undergoing deletional tolerance. Blood 2009;113: 4575-85.
40. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, et al. Signals required for programming effector and memory development by CD8+ T-cells. Immunol Rev 2006;211: 81-92.
41. Montfort MJ, Bouwer HG, Wagner CR, Hinrichs DJ. The development of functional CD8 T-cell memory after Listeria monocytogenes infection is not dependent on CD40. J Immunol 2004;173: 4084-90.
42. Khanna KM, Blair DA, Vella AT,McSorley SJ, Datta SK, Lefrancois L. Tcell and APC dynamics in situ control the outcome of vaccination. J Immunol 2010;185: 239-52.
43. Rudolph M, Hebel K, Miyamura Y, Maverakis E, Brunner-WeinzierlMC. Blockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T-cells in vivo. J Immunol 2011;186: 5580-9.
44. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg 2011;45: 341-60.
45. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12: 252-64.
46. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18: 2039-47.
47. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366: 2455-65.
48. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366: 2443-54.
49. Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD. Rescued tolerant CD8 T-cells are preprogrammed to reestablish the tolerant state. Science 2012;335: 723-7.
50. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T-cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10: 29-37.